<DOC>
	<DOCNO>NCT00574470</DOCNO>
	<brief_summary>The purpose study see whether serious graft versus host disease well control steroid treatment control therapy daclizumab infliximab . We hypothesize combination daclizumab infliximab effectively treat graft versus host disease therapy single drug . The study also look whether chronic graft versus host disease develop , survival 6 9 month post-treatment .</brief_summary>
	<brief_title>Anti Cytokine Combination Therapy With Daclizumab Infliximab Treatment Steroid Refractory Acute GVHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis steroid refractory aGVHD define response methylprednisolone 2 mg/kg 1 week disease progression 72 hour methylprednisolone dose . Potential subject decrease GVHD organ stag follow : Skin rash , present , decrease one stage . This base percent body involved rash , plus presence bulla desquamation . Gut GVHD , present , decrease one stage . This base volume diarrhea , pain , ileus . Upper gastrointestinal GVHD , present , resolve . Liver GVHD , present , decrease one stage . This base total bilirubin level . Prior allogeneic hematopoietic stem cell transplantation use bone marrow , peripheral blood umbilical cord cell . Recipients standard well nonmyeloablative transplant eligible . No previous immune suppressive therapy give treatment acute GVHD except corticosteroid . Absolute neutrophil count great 0.5x106/L . Estimated creatinine clearance great 30 mL/minute . Written informed consent Patient receive either infliximab daclizumab within seven day study . Patient uncontrolled infection exclude . Patients receive investigational agent GVHD prophylaxis treatment . Patients congestive heart failure . Patients history intolerance/ hypersensitivity daclizumab infliximab . Age le 18 year . Patients pregnant risk pregnancy unwilling use acceptable birth control method . Patients allergy murine product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>